Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Pieris Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Pieris Pharmaceuticals' CEO'su Steve Yoder, Dec2014 tarihinde atandı, in görev süresi 9.58 yıldır. in toplam yıllık tazminatı $ 1.36M olup, şirket hissesi ve opsiyonları dahil olmak üzere 43% maaş ve 57% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.006% ine doğrudan sahiptir ve bu hisseler € 499.80 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 6.7 yıldır.

Anahtar bilgiler

Steve Yoder

İcra Kurulu Başkanı

US$1.4m

Toplam tazminat

CEO maaş yüzdesi	43.0%
CEO görev süresi	9.6yrs
CEO sahipliği	0.006%
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	6.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Steve Yoder'un ücretlendirmesi Pieris Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$1m	US$585k	-US$25m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$2m	US$565k	-US$33m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$42m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$548k	-US$46m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$48m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$2m	US$535k	-US$37m
Sep 30 2020	n/a	n/a	-US$26m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$2m	US$515k	-US$28m
Sep 30 2019	n/a	n/a	-US$36m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$3m	US$500k	-US$27m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	US$1m	US$450k	-US$18m

Tazminat ve Piyasa: Steve 'nin toplam tazminatı ($USD 1.36M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 503.65K ).

Tazminat ve Kazançlar: Steve 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Steve Yoder (48 yo)

9.6yrs

Görev süresi

US$1,358,952

Tazminat

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Yoder	CEO, President & Director	9.6yrs	US$1.36m	0.0057% € 499.8
Thomas Bures	Senior VP	4.8yrs	US$729.04k	0.018% € 1.6k
Shane Olwill	Senior VP & Chief Development Officer	no data	US$705.45k	0.0044% € 386.3
Maria Kelman	Executive Director of Investor Relations	no data	Veri yok	Veri yok
Prompong Chaikul	Chief Supply Chain Officer	4.8yrs	Veri yok	Veri yok
Florian Witte	VP and Head of Alliance Management & Early Project Leadership	1.5yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: PI60 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Yoder	CEO, President & Director	9.6yrs	US$1.36m	0.0057% € 499.8
James Arthur Geraghty	Independent Chairman	7.2yrs	US$94.09k	0.019% € 1.7k
Michael Richman	Independent Director	9.6yrs	US$52.09k	0% € 0
Christopher Kiritsy	Independent Director	7.8yrs	US$72.58k	0.019% € 1.7k
Peter Kiener	Independent Director	5.8yrs	US$65.08k	0% € 0
Matthew Sherman	Independent Director	5.8yrs	US$53.09k	0% € 0
Ann Barbier	Independent Director	6.3yrs	US$52.09k	0% € 0
Maya Said	Independent Director	5yrs	US$52.09k	0% € 0
Ian Adcock	Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Oliver Eickelberg	Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Fan Chung	Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok
Peter Barnes	Member of Clinical & Scientific Advisory Board	no data	Veri yok	Veri yok

6.7yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PI60 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

Pieris Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Recent updates

Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. Announce Definitive Merger Agreement

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.13 loss in 3Q 2022)

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Insufficient new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.24 loss in 3Q 2021)

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.25 loss in 2Q 2021)

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.074 loss in 1Q 2021)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: €1.99

New 90-day high: €2.47

Third quarter 2020 earnings released: US$0.26 loss per share

Revenue misses expectations

New 90-day low: €1.94

Earnings released

New 90-day low - €2.16

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş